Spyre Therapeutics Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Public

  • Employees
  • 60

Employees

  • Stock Symbol
  • SYRE

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $22.92
  • (As of Friday Closing)

Spyre Therapeutics General Information

Description

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.

Contact Information

Website
www.spyre.com
Formerly Known As
Aeglea BioTherapeutics
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 221 Crescent Street
  • Suite 105
  • Waltham, MA 02453
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 221 Crescent Street
  • Suite 105
  • Waltham, MA 02453
  • United States

Spyre Therapeutics Timeline

20242025
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Spyre Therapeutics Stock Performance

As of 14-Feb-2025, Spyre Therapeutics’s stock price is $22.92. Its current market cap is $1.38B with 60.3M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$22.92 $22.68 $20.07 - $47.97 $1.38B 60.3M 609K -$1.50

Spyre Therapeutics Financials Summary

As of 30-Sep-2024, Spyre Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 1,227,374 958,678 (41,256) 127,003
Revenue 0 886 2,329 18,739
EBITDA (234,514) (344,219) (83,221) (64,195)
Net Income (214,902) (338,790) (83,815) (65,801)
Total Assets 421,089 341,859 71,144 109,926
Total Debt 0 0 4,629 5,060
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Spyre Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Spyre Therapeutics‘s full profile, request access.

Request a free trial

Spyre Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease
Drug Discovery
Waltham, MA
60 As of 2024

Cambridge, MA
 

Melbourne, Australia
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Spyre Therapeutics Competitors (66)

One of Spyre Therapeutics’s 66 competitors is Codiak BioSciences, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Codiak BioSciences Formerly VC-backed Cambridge, MA
Mesoblast Corporation Melbourne, Australia
Rhythm Pharmaceuticals Formerly VC-backed Boston, MA
Artizan Biosciences Venture Capital-Backed New Haven, CT
AnTolRx Venture Capital-Backed Cambridge, MA
You’re viewing 5 of 66 competitors. Get the full list »

Spyre Therapeutics Patents

Spyre Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20110200576-A1 Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof Active 04-Feb-2010
US-8709407-B2 Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof Active 04-Feb-2010
US-8679479-B2 Methods for purifying pegylated arginase Active 29-Jun-2009
US-20120177628-A1 Arginase formulations and methods Active 29-Jun-2009
US-9050340-B2 Compositions of engineered human arginases and methods for treating cancer Active 31-Oct-2008 A61K38/50
To view Spyre Therapeutics’s complete patent history, request access »

Spyre Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Spyre Therapeutics Acquisitions (1)

Spyre Therapeutics’s most recent deal was a Merger/Acquisition with Aeglea BioTherapeutics. The deal was made on 22-Jun-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Aeglea BioTherapeutics 22-Jun-2023 Merger/Acquisition Drug Discovery
To view Spyre Therapeutics’s complete acquisitions history, request access »

Spyre Therapeutics ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

34.16 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,912

Rank

Percentile

Pharmaceuticals

Industry

of 965

Rank

Percentile

Biotechnology

Subindustry

of 443

Rank

Percentile

To view Spyre Therapeutics’s complete esg history, request access »

Spyre Therapeutics FAQs

  • When was Spyre Therapeutics founded?

    Spyre Therapeutics was founded in 2023.

  • Where is Spyre Therapeutics headquartered?

    Spyre Therapeutics is headquartered in Waltham, MA.

  • What is the size of Spyre Therapeutics?

    Spyre Therapeutics has 60 total employees.

  • What industry is Spyre Therapeutics in?

    Spyre Therapeutics’s primary industry is Drug Discovery.

  • Is Spyre Therapeutics a private or public company?

    Spyre Therapeutics is a Public company.

  • What is Spyre Therapeutics’s stock symbol?

    The ticker symbol for Spyre Therapeutics is SYRE.

  • What is the current stock price of Spyre Therapeutics?

    As of 14-Feb-2025 the stock price of Spyre Therapeutics is $22.92.

  • What is the current market cap of Spyre Therapeutics?

    The current market capitalization of Spyre Therapeutics is $1.38B.

  • Who are Spyre Therapeutics’s competitors?

    Codiak BioSciences, Mesoblast, Rhythm Pharmaceuticals, Artizan Biosciences, and AnTolRx are some of the 66 competitors of Spyre Therapeutics.

  • What is Spyre Therapeutics’s annual earnings per share (EPS)?

    Spyre Therapeutics’s EPS for 12 months was -$1.50.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »